NASDAQ:CDXCChromadex Stock Price, Forecast & News

Chromadex's stock was trading at $3.68 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CDXC stock has increased by 30.7% and is now trading at $4.81.
View which stocks have been most impacted by COVID-19.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chromadex in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Chromadex.

Chromadex is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Chromadex.

Chromadex Corp (NASDAQ:CDXC) released its quarterly earnings data on Thursday, August, 6th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.05. Chromadex had a negative net margin of 46.86% and a negative return on equity of 103.66%.
View Chromadex's earnings history.

3 brokerages have issued 12-month price objectives for Chromadex's stock. Their forecasts range from $6.00 to $7.00. On average, they expect Chromadex's share price to reach $6.33 in the next twelve months. This suggests a possible upside of 31.7% from the stock's current price.
View analysts' price targets for Chromadex.

News headlines about CDXC stock have trended somewhat negative on Saturday, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Chromadex earned a news sentiment score of -1.4 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near term.
View the latest news about Chromadex.

Chromadex saw a decrease in short interest during the month of April. As of April 30th, there was short interest totaling 2,850,000 shares, a decrease of 17.9% from the April 15th total of 3,470,000 shares. Based on an average trading volume of 526,800 shares, the days-to-cover ratio is currently 5.4 days. Approximately 7.5% of the shares of the company are sold short.
View Chromadex's Short Interest.

Some companies that are related to Chromadex include Tilray (TLRY), Canopy Rivers (RIV), Mediwound (MDWD), Sundial Growers (SNDL), Happiness Biotech Group (HAPP), Natural Alternatives International (NAII), Mannatech (MTEX), Cyanotech (CYAN), True Drinks (TRUU), FitLife Brands (FTLF), GLG Life Tech (GLGLF), Tauriga Sciences (TAUG), Nutra Pharma (NPHC), Beleave (BE) and Beleave (BE).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chromadex investors own include Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Sorrento Therapeutics (SRNE), Heron Therapeutics (HRTX), Tilray (TLRY), Athersys (ATHX), Glu Mobile (GLUU), TransEnterix (TRXC), BioNano Genomics (BNGO) and DHT (DHT).

Chromadex trades on the NASDAQ under the ticker symbol "CDXC."

Chromadex's stock is owned by a variety of retail and institutional investors. Top institutional investors include Uniplan Investment Counsel Inc. (1.24%), Sycale Advisors NY LLC (0.59%), UBS Group AG (0.33%), Bank of New York Mellon Corp (0.21%), Bessemer Group Inc. (0.19%) and Raymond James Financial Services Advisors Inc. (0.14%). Company insiders that own Chromadex stock include Kevin M Farr, Robert N Fried and Stephen A Block.
View institutional ownership trends for Chromadex.

CDXC stock was sold by a variety of institutional investors in the last quarter, including Sargent Investment Group LLC, Miracle Mile Advisors LLC, UBS Group AG, Uniplan Investment Counsel Inc., Bank of New York Mellon Corp, and Raymond James Financial Services Advisors Inc..
View insider buying and selling activity for Chromadex.

CDXC stock was acquired by a variety of institutional investors in the last quarter, including Bessemer Group Inc., California Public Employees Retirement System, Sycale Advisors NY LLC, SG Americas Securities LLC, Insight 2811 Inc., Bank of America Corp DE, and Goldman Sachs Group Inc.. Company insiders that have bought Chromadex stock in the last two years include Kevin M Farr, and Robert N Fried.
View insider buying and selling activity for Chromadex.

Shares of CDXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CDXC stock can currently be purchased for approximately $4.81.

Chromadex has a market capitalization of $296.41 million and generates $46.29 million in revenue each year. The company earns $-32,150,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Chromadex employs 100 workers across the globe.

The official website for Chromadex is www.chromadex.com.

Chromadex's mailing address is 10900 Wilshire Blvd. Suite 650, Los Angeles CA, 90024. The company can be reached via phone at 310-388-6706 or via email at [email protected]